Literature DB >> 17290292

Choosing a mouse model to study the molecular pathobiology of Alport glomerulonephritis.

D Cosgrove1, R Kalluri, J H Miner, Y Segal, D-B Borza.   

Abstract

Alport syndrome, caused by mutations that interfere with the normal assembly of the alpha3alpha4alpha5(IV) collagen network in the glomerular basement membrane (GBM), is the most common inherited glomerular disease leading to renal failure. A detailed knowledge of the underlying pathogenic mechanisms is necessary for developing new, more specific, and effective therapeutic strategies aimed at delaying the onset and slowing disease progression. Studies of several dog and mouse models of Alport syndrome have significantly enhanced our understanding of the disease mechanisms and provided systems for testing potential therapies. In the most widely used Col4a3-/- mouse models of autosomal-recessive Alport syndrome (ARAS), the genetic background strongly affects renal survival. One contributing factor may be the strong ectopic deposition of alpha5alpha6(IV) collagen in the GBM of Col4a3-/- mice on the C57BL/6J background, which is almost undetectable on the 129/Sv background. This isoform 'switch' has not been observed in human ARAS, although it had been reported in the dog model of ARAS. In human patients as well as dog and mouse models of X-linked Alport syndrome, the alpha3-alpha6(IV) collagen chains are absent from the GBM. These biochemical differences among Alport animal models provide an opportunity to determine how the molecular makeup of the GBM affects the glomerular function. At the same time, potentially confounding influences of characteristics unique to a particular strain or model should be carefully considered in the design of studies aiming to define key events underlying the pathobiology of Alport glomerular disease.

Entities:  

Mesh:

Year:  2007        PMID: 17290292     DOI: 10.1038/sj.ki.5002115

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  22 in total

1.  The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice.

Authors:  Thaddeus J Wadas; Christopher D Sherman; Jeffrey H Miner; James R Duncan; Carolyn J Anderson
Journal:  Magn Reson Med       Date:  2010-11       Impact factor: 4.668

2.  Genetic background influences cardiac phenotype in murine chronic kidney disease.

Authors:  Samantha Neuburg; Corey Dussold; Claire Gerber; Xueyan Wang; Connor Francis; Lixin Qi; Valentin David; Myles Wolf; Aline Martin
Journal:  Nephrol Dial Transplant       Date:  2018-07-01       Impact factor: 5.992

Review 3.  The triple helix of collagens - an ancient protein structure that enabled animal multicellularity and tissue evolution.

Authors:  Aaron L Fidler; Sergei P Boudko; Antonis Rokas; Billy G Hudson
Journal:  J Cell Sci       Date:  2018-04-09       Impact factor: 5.285

4.  Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits.

Authors:  Wen Ding; Keyvan Yousefi; Stefania Goncalves; Bradley J Goldstein; Alfonso L Sabater; Amy Kloosterboer; Portia Ritter; Guerline Lambert; Armando J Mendez; Lina A Shehadeh
Journal:  JCI Insight       Date:  2018-03-22

5.  Stem cell therapies benefit Alport syndrome.

Authors:  Valerie LeBleu; Hikaru Sugimoto; Thomas M Mundel; Behzad Gerami-Naini; Elizabeth Finan; Caroline A Miller; Vincent H Gattone; Lingge Lu; Charles F Shield; Judah Folkman; Raghu Kalluri
Journal:  J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 10.121

Review 6.  Cell Receptor-Basement Membrane Interactions in Health and Disease: A Kidney-Centric View.

Authors:  Corina M Borza; Xiwu Chen; Roy Zent; Ambra Pozzi
Journal:  Curr Top Membr       Date:  2015       Impact factor: 3.049

Review 7.  Familial hematuria.

Authors:  Clifford E Kashtan
Journal:  Pediatr Nephrol       Date:  2007-10-02       Impact factor: 3.714

8.  Biomechanical strain causes maladaptive gene regulation, contributing to Alport glomerular disease.

Authors:  Daniel T Meehan; Duane Delimont; Linda Cheung; Marisa Zallocchi; Steven C Sansom; J David Holzclaw; Velidi Rao; Dominic Cosgrove
Journal:  Kidney Int       Date:  2009-08-26       Impact factor: 10.612

9.  Albumin contributes to kidney disease progression in Alport syndrome.

Authors:  George Jarad; Russell H Knutsen; Robert P Mecham; Jeffrey H Miner
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-04

10.  Feasibility of repairing glomerular basement membrane defects in Alport syndrome.

Authors:  Xiaobo Lin; Jung Hee Suh; Gloriosa Go; Jeffrey H Miner
Journal:  J Am Soc Nephrol       Date:  2013-11-21       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.